{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T07:05:16Z","timestamp":1781852716618,"version":"3.54.5"},"update-to":[{"DOI":"10.1002\/14651858.cd013103","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T00:00:00Z","timestamp":1568246400000}}],"reference-count":148,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013103.pub2","type":"journal-article","created":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T13:07:03Z","timestamp":1568293623000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis"],"prefix":"10.1002","volume":"2019","author":[{"given":"Lawrence MJ","family":"Best","sequence":"first","affiliation":[{"name":"University College London; Division of Surgery and Interventional Science; Rowland Hill Street London UK NW32PF"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne C","family":"Freeman","sequence":"additional","affiliation":[{"name":"University of Leicester; Department of Health Sciences; University Road Leicester UK LE1 7RH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex J","family":"Sutton","sequence":"additional","affiliation":[{"name":"University of Leicester; Department of Health Sciences; University Road Leicester UK LE1 7RH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola J","family":"Cooper","sequence":"additional","affiliation":[{"name":"University of Leicester; Department of Health Sciences; University Road Leicester UK LE1 7RH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eng-Loon","family":"Tng","sequence":"additional","affiliation":[{"name":"Ng Teng Fong General Hospital National University Health System; Department of Medicine; 1 Jurong East Street 21 Singapore Singapore 609606"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Csenar","sequence":"additional","affiliation":[{"name":"University College London; Division of Surgery and Interventional Science; Rowland Hill Street London UK NW32PF"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Hawkins","sequence":"additional","affiliation":[{"name":"University of Glasgow; HEHTA; University Ave Glasgow G12 8QQ Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chavdar S","family":"Pavlov","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital; Cochrane Hepato-Biliary Group; Blegdamsvej 9 Copenhagen Denmark DK-2100"},{"name":"'Sechenov' First Moscow State Medical University; Center for Evidence-Based Medicine; Pogodinskja st. 1\\1 Moscow Russian Federation 119881"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian R","family":"Davidson","sequence":"additional","affiliation":[{"name":"University College London; Division of Surgery and Interventional Science; Rowland Hill Street London UK NW32PF"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Thorburn","sequence":"additional","affiliation":[{"name":"Royal Free Hospital and the UCL Institute of Liver and Digestive Health; Sheila Sherlock Liver Centre; Pond Street London UK NW3 2QG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxine","family":"Cowlin","sequence":"additional","affiliation":[{"name":"PSC Support; PO Box 6945 London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth Jane","family":"Milne","sequence":"additional","affiliation":[{"name":"Coventry University; Centre for Trust, Peace and Social Relations; Coventry UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Tsochatzis","sequence":"additional","affiliation":[{"name":"Royal Free Hospital and the UCL Institute of Liver and Digestive Health; Sheila Sherlock Liver Centre; Pond Street London UK NW3 2QG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurinchi Selvan","family":"Gurusamy","sequence":"additional","affiliation":[{"name":"University College London; Division of Surgery and Interventional Science; Rowland Hill Street London UK NW32PF"},{"name":"'Sechenov' First Moscow State Medical University; Center for Evidence-Based Medicine; Pogodinskja st. 1\\1 Moscow Russian Federation 119881"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,9,12]]},"reference":[{"key":"10.1002\/14651858.CD013103.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/S0168-8278(06)80204-7","article-title":"Noradrenaline vs terlipressin in hepatorenal syndrome: a prospective, randomized study","volume":"44 Suppl 2","author":"Alessandria","year":"2006","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD013103.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jhep.2007.04.010","article-title":"Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study","volume":"47","author":"Alessandria","year":"2007","journal-title":"Journal of Hepatology"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD013103.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"S563","DOI":"10.1016\/S0168-8278(17)31542-8","article-title":"Terlipressin is superior to Noradrenaline in the management of acute kidney injury (AKI) in patients with ACLF","volume":"66","author":"Arora","year":"2017","journal-title":"Journal of Hepatology"},{"issue":"1 Supplement 1","key":"10.1002\/14651858.CD013103.pub2-BIB0004|cit4","first-page":"S7","article-title":"Terlipressin is superior to noradrenaline in management of acute kidney injury in acute on chronic liver failure","volume":"36","author":"Arora","year":"2017","journal-title":"Indian Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0005|cit5","unstructured":"Arora V Maiwall R Vijayaraghavan R Jindal A Saggere Muralikrishna S Kumar G Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure Hepatology 10.1002\/hep.30208"},{"issue":"1","key":"10.1002\/14651858.CD013103.pub2-BIB0006|cit6","first-page":"13","article-title":"Norepinephrine versus terlipressin in patients with type 1 hepatorenal syndrome refractory to treatment with octreotide, midodrine, and albumin (a prospective randomized comparative study)","volume":"7","author":"Badawy","year":"2013","journal-title":"Egyptian Journal of Cardiothoracic Anesthesia"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0007|cit7","first-page":"S255","article-title":"Initial report of a large, randomized, double blind, placebo-controlled, phase 3 trial of terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome (HRS-1): the reverse study","volume":"60 Suppl 1","author":"Boyer","year":"2014","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0008|cit8","first-page":"39","article-title":"A randomized, placebo-controlled, double-blind study to confirm the reversal of hepatorenal syndrome type 1 with terlipressin: the reverse trial design","volume":"4","author":"Boyer","year":"2012","journal-title":"Journal of Clinical Trials (open access)"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"S379","DOI":"10.1016\/S0168-8278(15)30417-7","article-title":"Percentage change in serum creatinine (SCR) is a sensitive indicator of therapeutic response to terlipressin in hepatorenal syndrome type 1 (HRS-1)","volume":"62 Suppl 2","author":"Boyer","year":"2015","journal-title":"Journal of Hepatology"},{"issue":"7","key":"10.1002\/14651858.CD013103.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1053\/j.gastro.2016.02.026","article-title":"Terlipressin plus albumin Is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1","volume":"150","author":"Boyer","year":"2016","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD013103.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/hep.27709","article-title":"Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial","volume":"62","author":"Cavallin","year":"2015","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0012|cit12","first-page":"S1426","article-title":"Terlipressin and albumin vs midodrine plus octreotide and albumin in the treatment of hepatorenal syndrome in patients with cirrhosis: results of a controlled clinical trial by the Italian Association for the Study of the Liver","volume":"54 Suppl 1","author":"Cavallin","year":"2011","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0013|cit13","first-page":"56","article-title":"Captopril in low dose associated with octreotide in hepatorenal syndrome: a randomized study","volume":"38","author":"Chelarescu","year":"2003","journal-title":"Journal of Hepatology"},{"key":"#cr-split#-10.1002\/14651858.CD013103.pub2-BIB0014|cit14.1","unstructured":"London (UK) http:\/\/www.falk-foundation-symposia.org\/uploads\/tx_tocfpshoperw\/FS191_London_Abstracts_03.pdf Falk Foundation 2013 87"},{"key":"#cr-split#-10.1002\/14651858.CD013103.pub2-BIB0014|cit14.2","unstructured":"Copaci I Chiriac G Micu L Mindrut E Alternative treatments for hepato-renal syndrome in patients with cirrhosis Falk Symposium 191. Liver Diseases in 2013: Advances in Pathogenesis and Treatment; 2013 Oct 4-5; London"},{"key":"#cr-split#-10.1002\/14651858.CD013103.pub2-BIB0014|cit14.3","unstructured":"(UK) http:\/\/www.falk-foundation-symposia.org\/uploads\/tx_tocfpshoperw\/FS191_London_Abstracts_03.pdf Falk Foundation 2013 87"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"S660","DOI":"10.1016\/S0168-8278(16)01240-X","article-title":"Reversal of type 1 hepatorenal syndrome with terlipressin and octreotide","volume":"64 Suppl 2","author":"Copaci","year":"2016","journal-title":"Journal of Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD013103.pub2-BIB0016|cit16","first-page":"1655","article-title":"Randomized trial of peritoneovenous shunt in the treatment of hepatorenal syndrome (HRS)","volume":"88","author":"Daskalopoulos","year":"1985","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1002\/14651858.CD013103.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/liv.12179","article-title":"Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study","volume":"33","author":"Ghosh","year":"2013","journal-title":"Liver International"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD013103.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"S958","DOI":"10.1016\/S0016-5085(11)63969-3","article-title":"Noradrenaline versus terlipressin in the treatment of hepatorenal syndrome","volume":"140","author":"Singh","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0019|cit19","first-page":"A98","article-title":"Noradrenaline versus terlipressin in the treatment of hepatorenal syndrome","volume":"25 Suppl 2","author":"Singh","year":"2010","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0020|cit20","first-page":"A76","article-title":"Terlipressin versus noradrenalin in hepatorenal syndrome: a prospective, randomised, unblinded study","volume":"23 Suppl 5","author":"Goyal","year":"2008","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"9","key":"10.1002\/14651858.CD013103.pub2-BIB0021|cit21","first-page":"30","article-title":"Noradrenaline is as effective as terlipressin in hepatorenal syndrome type 1: a prospective, randomized trial","volume":"64","author":"Goyal","year":"2016","journal-title":"Journal of the Association of Physicians of India"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/j.jceh.2013.02.242","article-title":"Noradrenaline is equally effective as terlipressin in reversal of type 1 hepatorenal syndrome: a randomized prospective study","volume":"3 Suppl 1","author":"Indrabi","year":"2013","journal-title":"Journal of Clinical and Experimental Hepatology"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0023|cit23","first-page":"350","article-title":"Racehorse: a randomized controlled trial on goal-directed therapy of hepatorenal syndrome","volume":"4 Suppl 1","author":"Koch","year":"2016","journal-title":"Intensive Care Medicine Experimental"},{"issue":"5","key":"10.1002\/14651858.CD013103.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1053\/j.gastro.2008.02.024","article-title":"Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study","volume":"134","author":"Martin-Llahi","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/S0168-8278(07)61680-8","article-title":"Randomized, comparative study of terlipressin and albumin vs albumin alone in patients with cirrhosis and hepatorenal syndrome","volume":"46 Suppl 1","author":"Martin-Llahi","year":"2007","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0026|cit26","first-page":"818A","article-title":"Terlipressin and albumin significantly improved renal function in patients with type I hepatorenal syndrome (HRS) enrolled in a randomized, double-blind, placebo controlled trial","volume":"18 Suppl 1","author":"Whittman","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD013103.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1053\/lv.2000.6355","article-title":"Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial","volume":"6","author":"Mitzner","year":"2000","journal-title":"Liver Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD013103.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s10620-007-9919-9","article-title":"Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome","volume":"53","author":"Neri","year":"2008","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0029|cit29","first-page":"34","article-title":"Low doses of terlipressin and albumin in type I hepatorenal syndrome","volume":"2","author":"Pulvirenti","year":"2008","journal-title":"Italian Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD013103.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s12664-018-0876-3","article-title":"Noradrenaline versus terlipressin in the management of type 1 hepatorenal syndrome: a randomized controlled study","volume":"37","author":"Saif","year":"2018","journal-title":"Indian Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0031|cit31","first-page":"450","article-title":"Liver transplant affects survival outcomes in patients (pts) with type 1 hepatorenal syndrome (HRS) treated with terlipressin vs placebo","volume":"9","author":"Boyer","year":"2009","journal-title":"American Journal of Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD013103.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2010.11.020","article-title":"Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics","volume":"55","author":"Boyer","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"11","key":"10.1002\/14651858.CD013103.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1002\/lt.22395","article-title":"Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1","volume":"17","author":"Boyer","year":"2011","journal-title":"Liver Transplantation"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0034|cit34","first-page":"694A","article-title":"A prospective, randomized, double blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome (HRS)","volume":"44 Suppl 1","author":"Sanyal","year":"2006","journal-title":"Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD013103.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1053\/j.gastro.2008.02.014","article-title":"A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome","volume":"134","author":"Sanyal","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0036|cit36","first-page":"1071a","article-title":"Effect of terlipressin on mean arterial pressure (MAP) and its relation to serum creatinine concentration (SCr) in type 1 hepatorenal syndrome (HRS): analysis of data from the pivotal phase 3 trial","volume":"48 Suppl 1","author":"Sanyal","year":"2008","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0037|cit37","first-page":"564a","article-title":"Prognostic factors for hepatorenal syndrome (HRS) reversal in patients with type 1 HRS enrolled in a randomized, double-blind, placebo-controlled trial","volume":"46 Suppl 1","author":"Sanyal","year":"2007","journal-title":"Hepatology"},{"issue":"7","key":"10.1002\/14651858.CD013103.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/j.1572-0241.2008.01828.x","article-title":"An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response","volume":"103","author":"Sharma","year":"2008","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0039|cit39","first-page":"449A","article-title":"Nor adrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome: a randomized controlled trial","volume":"44 Suppl 1","author":"Sharma","year":"2006","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD013103.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jhep.2012.01.012","article-title":"Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study","volume":"56","author":"Singh","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD013103.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1046\/j.1440-1746.2003.02934.x","article-title":"Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial","volume":"18","author":"Solanki","year":"2003","journal-title":"Journal of Gastroenterology & Hepatology"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0042|cit42","first-page":"958a","article-title":"Treatment of type-1 hepatorenal syndrome with pentoxifylline: a randomized placebo controlled, blinded pilot clinical trial","volume":"66 Suppl 1","author":"Stine","year":"2017","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD013103.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"300","DOI":"10.5604\/01.3001.0010.8661","article-title":"Treatment of type-1 hepatorenal syndrome with pentoxifylline: a randomized placebo controlled clinical trial","volume":"17","author":"Stine","year":"2018","journal-title":"Annals of Hepatology"},{"issue":"11","key":"10.1002\/14651858.CD013103.pub2-BIB0044|cit44","first-page":"764","article-title":"Noradrenalin versus the combination of midodrine and octreotide in patients with hepatorenal syndrome: randomized clinical trial","volume":"3","author":"Tavakkoli","year":"2012","journal-title":"International Journal of Preventive Medicine"},{"issue":"3","key":"10.1002\/14651858.CD013103.pub2-BIB0045|cit45","first-page":"123","article-title":"Efficacy of terlipressin in treatment of liver cirrhosis with hepatorenal syndrome","volume":"7","author":"Yang","year":"2001","journal-title":"Journal of Internal Intensive Medicine"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.14309\/00000434-201210001-00418","article-title":"Role of terlipressin and albumin combination versus albumin alone in hepatorenal syndrome","volume":"107 Suppl 1","author":"Zafar","year":"2012","journal-title":"American Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD013103.pub2-BIB0047|cit47","first-page":"261","article-title":"Possible increased risk of pulmonary edema in patients with hepatorenal syndrome on adding octreotide to albumin\/noradrenaline therapies","volume":"18","author":"Abutaleb","year":"2007","journal-title":"Saudi Journal of Kidney Diseases & Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD013103.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1111\/j.1572-0241.2002.05847.x","article-title":"Effect of misoprostol on lbuprofen-induced renal dysfunction in patients with decompensated cirrhosis: results of a double-blind placebo-controlled parallel group study","volume":"97","author":"Ackerman","year":"2002","journal-title":"American Journal of Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD013103.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/hep.510290629","article-title":"Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide","volume":"29","author":"Angeli","year":"1999","journal-title":"Hepatology"},{"issue":"11","key":"10.1002\/14651858.CD013103.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/lt.24339","article-title":"Is type 2 hepatorenal syndrome still a potential indication for treatment with terlipressin and albumin?","volume":"21","author":"Angeli","year":"2015","journal-title":"Liver Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD013103.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1053\/jhep.2003.50108","article-title":"Terlipressin and albumin for the hepatorenal syndrome","volume":"37","author":"Antoniades","year":"2003","journal-title":"Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD013103.pub2-BIB0052|cit52","first-page":"184","article-title":"Reversal of hepatorenal syndrome with oral misoprostol. Is the dose the key to the response?","volume":"19","author":"Casado Caballero","year":"1996","journal-title":"Gastroenterologia y Hepatologia"},{"issue":"1","key":"10.1002\/14651858.CD013103.pub2-BIB0053|cit53","first-page":"54","article-title":"Prostaglandins for the treatment of hepatorenal syndrome","volume":"28","author":"Clewell","year":"1994","journal-title":"Annals of Pharmacotherapy"},{"issue":"12","key":"10.1002\/14651858.CD013103.pub2-BIB0054|cit54","first-page":"3645","article-title":"Prolonged infusion of ornithine plus dopamine in the treatment of the hepatorenal syndrome: a breakthrough?","volume":"95","author":"Conn","year":"2000","journal-title":"American Journal of Gastroenterology"},{"issue":"10","key":"10.1002\/14651858.CD013103.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1111\/j.1572-0241.2000.03214.x","article-title":"Hepatorenal syndrome in cirrhotic patients: terlipressine is a safe and efficient treatment; propranolol and digitalic treatments: precipitating and preventing factors?","volume":"95","author":"Duhamel","year":"2000","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0056|cit56","doi-asserted-by":"crossref","unstructured":"Durkin RJ Winter SM Reversal of hepatorenal syndrome with the combination of norepinephrine and dopamine Critical Care Medicine 1995 202 4","DOI":"10.1097\/00003246-199501000-00031"},{"issue":"2","key":"10.1002\/14651858.CD013103.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jhep.2014.09.030","article-title":"Transient increase in urine protein excretion during treatment with terlipressin and albumin for type-1 hepatorenal syndrome","volume":"62","author":"Elia","year":"2015","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD013103.pub2-BIB0058|cit58","first-page":"80","article-title":"Role of albumin in the treatment of hepatorenal syndrome in cirrhosis","volume":"28","author":"Gines","year":"2005","journal-title":"Gastroenterologia y Hepatologia"},{"issue":"1","key":"10.1002\/14651858.CD013103.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/0168-8278(95)80273-8","article-title":"Sustained effects of ornipressin in hepatorenal syndrome","volume":"22","author":"Giostra","year":"1995","journal-title":"Journal of Hepatology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD013103.pub2-BIB0060|cit60","first-page":"165a","article-title":"Terlipressin in the treatment of hepatorenal syndrome (HRS): a double blind cross-over study","volume":"22","author":"Hadengue","year":"1995","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD013103.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0168-8278(98)80151-7","article-title":"Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome","volume":"29","author":"Hadengue","year":"1998","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD013103.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0168-8278(99)80025-7","article-title":"Octreotide in the treatment of the hepatorenal syndrome in cirrhotic patients","volume":"30","author":"Kaffy","year":"1999","journal-title":"Journal of Hepatology"},{"issue":"9","key":"10.1002\/14651858.CD013103.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.amjmed.2005.04.007","article-title":"Terlipressin avoids hemodialysis in the treatment of refractory hyperkalemia associated with renal dysfunction in cirrhosis","volume":"118","author":"Kalambokis","year":"2005","journal-title":"American Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD013103.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1097\/MEG.0000000000000988","article-title":"Terlipressin is superior to midodrine\/octreotide for hepatorenal syndrome type 1","volume":"29","author":"Kalambokis","year":"2017","journal-title":"European Journal of Gastroenterology & Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD013103.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1053\/jhep.2002.0350492","article-title":"Treatment of hepatorenal syndrome: lessons from the MARS trial","volume":"35","author":"Mullen","year":"2002","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0066|cit66","first-page":"61","article-title":"Effects of administration of terlipressin with or without albumin in hepatorenal syndrome. Phase II study","volume":"25 (Suppl 1)","author":"Ortega","year":"2002","journal-title":"Gastroenterologia y Hepatologia"},{"issue":"6","key":"10.1002\/14651858.CD013103.pub2-BIB0067|cit67","first-page":"482","article-title":"Effectiveness of terlipressin in hepatorenal syndrome is confirmed","volume":"15","author":"Pauwels","year":"2008","journal-title":"H\u00e9pato-Gastro & Oncologie Digestive"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD013103.pub2-BIB0068|cit68","first-page":"544A","article-title":"Octreotide in hepatorenal syndrome: a randomized placebo-controlled cross-over study","volume":"34","author":"Pomier-Layrargues","year":"2001","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD013103.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1053\/jhep.2003.50276","article-title":"Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study","volume":"38","author":"Pomier-Layrargues","year":"2003","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD013103.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1002\/hep.27154","article-title":"Continuous outpatient terlipressin infusion for hepatorenal syndrome as a bridge to successful liver transplantation","volume":"60","author":"Robertson","year":"2014","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD013103.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jceh.2015.08.003","article-title":"Randomized controlled trial comparing the efficacy of terlipressin and albumin with a combination of concurrent dopamine, furosemide, and albumin in hepatorenal syndrome","volume":"5","author":"Srivastava","year":"2015","journal-title":"Journal of Clinical & Experimental Hepatology"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0072|cit72","first-page":"359","article-title":"Treatment of the hepatorenal syndrome with metaraminol","volume":"21","author":"Sugerman","year":"1970","journal-title":"Surgical Forum"},{"issue":"3","key":"10.1002\/14651858.CD013103.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1056\/NEJM197107152850321","article-title":"Metaraminol in \"hepatorenal syndrome\"","volume":"285","author":"Sugerman","year":"1971","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD013103.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1111\/j.1440-1746.2009.06034.x","article-title":"Targeting circulatory dysfunction in cirrhosis: terlipressin and the hepatorenal syndrome","volume":"24","author":"Testro","year":"2009","journal-title":"Journal of Gastroenterology & Hepatology"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0075|cit75","first-page":"69","article-title":"Comparative study of treatment with noradrenaline versus terlipressin in patients with hepatorenal syndrome type 1","volume":"27 Suppl 1","author":"Valer-Fand\u00f3","year":"2004","journal-title":"Gastroenterolog\u00eda y Hepatolog\u00eda"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0076|cit76","first-page":"A5789","article-title":"High versus low mean arterial pressures in hepatorenal syndrome: a randomized controlled trial","volume":"195","author":"Varajic","year":"2017","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0077|cit77","unstructured":"NCT02770716 A study to confirm efficacy and safety of terlipressin in HRS type 1 clinicaltrials.gov\/ct2\/show\/NCT02770716"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0078|cit78","unstructured":"NCT03455322 Norepinephrine infusion versus midodrine & octreotide in patients with hepatorenal syndrome type 1 clinicaltrials.gov\/ct2\/show\/NCT03455322"},{"issue":"6","key":"10.1002\/14651858.CD013103.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"293","DOI":"10.4254\/wjh.v9.i6.293","article-title":"Hepatorenal syndrome: update on diagnosis and therapy","volume":"9","author":"Acevedo","year":"2017","journal-title":"World Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD013103.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jhep.2012.04.015","article-title":"Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR)","volume":"57","author":"Adam","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD013103.pub2-BIB0081|cit81","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005162.pub4","article-title":"Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome","author":"Allegretti","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD013103.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.jhep.2014.12.029","article-title":"Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites","volume":"62","author":"Angeli","year":"2015","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD013103.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/hep.510230122","article-title":"Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club","volume":"23","author":"Arroyo","year":"1996","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD013103.pub2-BIB0084|cit84","first-page":"259","article-title":"The clinical use of albumin: the point of view of a specialist in intensive care","volume":"7","author":"Caironi","year":"2009","journal-title":"Trasfusione del Sangue"},{"issue":"2","key":"10.1002\/14651858.CD013103.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/jrsm.57","article-title":"Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions","volume":"3","author":"Chaimani","year":"2012","journal-title":"Research Synthesis Methods"},{"issue":"10","key":"10.1002\/14651858.CD013103.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLOS ONE"},{"issue":"3","key":"10.1002\/14651858.CD013103.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","article-title":"SPIRIT 2013 statement: defining standard protocol items for clinical trials","volume":"158","author":"Chan","year":"2013","journal-title":"Annals of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD013103.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","author":"Franchis","year":"2015","journal-title":"Journal of Hepatology"},{"issue":"7-8","key":"10.1002\/14651858.CD013103.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0090|cit90","unstructured":"Dias S Sutton AJ Welton NJ Ades AE NICE DSU technical support document 3: heterogeneity: subgroups, meta-regression, bias and bias-adjustment, September 2011 (last updated April 2012) nicedsu.org.uk\/wp-content\/uploads\/2016\/03\/TSD3-Heterogeneity.final-report.08.05.12.pdf"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0091|cit91","unstructured":"Dias S Welton NJ Sutton AJ Ades AE NICE DSU technical support document 1: introduction to evidence synthesis for decision making, April 2011 (last updated April 2012) nicedsu.org.uk\/wp-content\/uploads\/2016\/03\/TSD1-Introduction.final_.08.05.12.pdf"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0092|cit92","unstructured":"Dias S Welton NJ Sutton AJ Caldwell DM Lu G Ades AE NICE DSU technical support document 4: inconsistency in networks of evidence based on randomised controlled trials, May 2011 (last updated April 2014) nicedsu.org.uk\/wp-content\/uploads\/2016\/03\/TSD4-Inconsistency.final_.15April2014.pdf"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0093|cit93","unstructured":"Dias S Welton NJ Sutton AJ Ades AE NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials, August 2011 (last updated September 2016) nicedsu.org.uk\/wp-content\/uploads\/2017\/05\/TSD2-General-meta-analysis-corrected-2Sep2016v2.pdf"},{"issue":"12","key":"10.1002\/14651858.CD013103.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1007\/s10620-016-4313-0","article-title":"Rifaximin decreases the incidence and severity of acute kidney injury and hepatorenal syndrome in cirrhosis","volume":"61","author":"Dong","year":"2016","journal-title":"Digestive Diseases and Sciences"},{"issue":"2","key":"10.1002\/14651858.CD013103.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2015.10.006","article-title":"EASL Clinical Practice Guidelines: liver transplantation","volume":"64","author":"European Association for the Study of the Liver","year":"2016","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0096|cit96","unstructured":"European Association for the Study of the Liver EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis Journal of Hepatology 10.1016\/j.jhep.2018.03.024"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0097|cit97","unstructured":"EuroQol EQ-5D Instruments: about EQ-5D, 2018 euroqol.org\/eq-5d-instruments\/"},{"issue":"5","key":"10.1002\/14651858.CD013103.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jhep.2008.05.023","article-title":"Incidence and prevalence of cirrhosis in the United Kingdom, 1992-2001: a general population-based study","volume":"49","author":"Fleming","year":"2008","journal-title":"Journal of Hepatology"},{"issue":"13","key":"10.1002\/14651858.CD013103.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMra0809139","article-title":"Renal failure in cirrhosis","volume":"361","author":"Gines","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0100|cit100","unstructured":"Gluud C Nikolova D Klingenberg SL Cochrane Hepato-Biliary Group About Cochrane (Cochrane Review Groups (CRGs)) 2016, Issue 10. Art. No.: LIVER"},{"issue":"3","key":"10.1002\/14651858.CD013103.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"e025045","DOI":"10.1136\/bmjopen-2018-025045","article-title":"Top research priorities in liver and gallbladder disorders in the UK","volume":"9","author":"Gurusamy","year":"2019","journal-title":"BMJ Open"},{"issue":"4","key":"10.1002\/14651858.CD013103.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0103|cit103","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"2","key":"10.1002\/14651858.CD013103.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Research Synthesis Methods"},{"issue":"3","key":"10.1002\/14651858.CD013103.pub2-BIB0105|cit105","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011039","article-title":"Transjugular intrahepatic portosystemic shunts for hepatorenal syndrome","author":"Hinojosa-Azaola","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD013103.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0107|cit107","volume-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice CFR & ICH Guidelines","volume":"1","author":"International Conference on Harmonisation Expert Working Group","year":"1997"},{"issue":"9","key":"10.1002\/14651858.CD013103.pub2-BIB0108|cit108","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011532.pub2","article-title":"Terlipressin versus other vasoactive drugs for hepatorenal syndrome","author":"Israelsen","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"21","key":"10.1002\/14651858.CD013103.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1002\/sim.6188","article-title":"A design-by-treatment interaction model for network meta-analysis with random inconsistency effects","volume":"33","author":"Jackson","year":"2014","journal-title":"Statistics in Medicine"},{"issue":"11","key":"10.1002\/14651858.CD013103.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses","volume":"135","author":"Kjaergard","year":"2001","journal-title":"Annals of Internal Medicine"},{"issue":"474","key":"10.1002\/14651858.CD013103.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1198\/016214505000001302","article-title":"Assessing evidence inconsistency in mixed treatment comparisons","volume":"101","author":"Lu","year":"2006","journal-title":"Journal of the American Statistical Association"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"i124","DOI":"10.1136\/bmj.i124","article-title":"Decompensated alcohol related liver disease: acute management","volume":"352","author":"McPherson","year":"2016","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD013103.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1055\/s-0030-1267541","article-title":"Current status and future of liver transplantation","volume":"30","author":"Merion","year":"2010","journal-title":"Seminars in Liver Disease"},{"issue":"12","key":"10.1002\/14651858.CD013103.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1001\/2012.jama.11228","article-title":"How to use an article reporting a multiple treatment comparison meta-analysis","volume":"308","author":"Mills","year":"2012","journal-title":"JAMA"},{"issue":"9128","key":"10.1002\/14651858.CD013103.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12916-014-0145-y","article-title":"Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis","volume":"12","author":"Mokdad","year":"2014","journal-title":"BMC Medicine"},{"issue":"4","key":"10.1002\/14651858.CD013103.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/MCG.0000000000000913","article-title":"Pharmacological therapies for hepatorenal syndrome: a systematic review and meta-analysis","volume":"52","author":"Nanda","year":"2018","journal-title":"Journal of Clinical Gastroenterology"},{"issue":"9","key":"10.1002\/14651858.CD013103.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"e107466","DOI":"10.1371\/journal.pone.0107466","article-title":"Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis","volume":"9","author":"Nassar Junior","year":"2014","journal-title":"PLOS One"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0119|cit119","unstructured":"NCBI Liver cirrhosis www.ncbi.nlm.nih.gov\/mesh\/68008103"},{"issue":"5","key":"10.1002\/14651858.CD013103.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/ije\/21.5.837","article-title":"Intention-to-treat analysis: implications for quantitative and qualitative research","volume":"21","author":"Newell","year":"1992","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0121|cit121","unstructured":"Members of OpenBUGS Project Management Group OpenBUGS 2014"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0122|cit122","unstructured":"Optum Patient-reported outcomes | what we do | SF health surveys | SF-36v2 Health Survey, 2018 campaign.optum.com\/optum-outcomes\/what-we-do\/health-surveys\/sf-36v2-health-survey.html"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"g5630","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"issue":"8","key":"10.1002\/14651858.CD013103.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/ajg.2015.191","article-title":"Causes of death in people with liver cirrhosis in England compared with the general population: a population-based cohort study","volume":"110","author":"Ratib","year":"2015","journal-title":"American Journal of Gastroenterology"},{"issue":"9","key":"10.1002\/14651858.CD013103.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/bja\/44.9.910","article-title":"Clinical physiology of the liver","volume":"44","author":"Read","year":"1972","journal-title":"British Journal of Anaesthesia"},{"issue":"8","key":"10.1002\/14651858.CD013103.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1080\/03007995.2017.1331211","article-title":"The burden of hepatorenal syndrome among commercially insured and Medicare patients in the United States","volume":"33","author":"Rice","year":"2017","journal-title":"Current Medical Research and Opinion"},{"issue":"4","key":"10.1002\/14651858.CD013103.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1017\/S0266462303000552","article-title":"Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches","volume":"19","author":"Royle","year":"2003","journal-title":"International Journal of Technology Assessment in Health Care"},{"issue":"2","key":"10.1002\/14651858.CD013103.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD013103.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1037","article-title":"Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool","volume":"3","author":"Salanti","year":"2012","journal-title":"Research Synthesis Methods"},{"issue":"35","key":"10.1002\/14651858.CD013103.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16350","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomized controlled trials: combined analysis of meta-epidemiological studies","volume":"16","author":"Savovi\u0107","year":"2012","journal-title":"Health Technology Assessment"},{"issue":"6","key":"10.1002\/14651858.CD013103.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"429","DOI":"10.7326\/0003-4819-157-6-201209180-00537","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomized controlled trials","volume":"157","author":"Savovi\u0107","year":"2012","journal-title":"Annals of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD013103.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/aje\/kwx344","article-title":"Association between risk-of-bias assessments and results of randomized trials in Cochrane Reviews: the ROBES meta-epidemiologic study","volume":"187","author":"Savovi\u0107","year":"2018","journal-title":"American Journal of Epidemiology"},{"issue":"8","key":"10.1002\/14651858.CD013103.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/MCG.0000000000000208","article-title":"The epidemiology of cirrhosis in the United States: a population-based study","volume":"49","author":"Scaglione","year":"2015","journal-title":"Journal of Clinical Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD013103.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ (Clinical Research Ed)"},{"issue":"6","key":"10.1002\/14651858.CD013103.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/hep.28677","article-title":"Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: the multiethnic cohort","volume":"64","author":"Setiawan","year":"2016","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD013103.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.2517-6161.1993.tb01921.x","article-title":"Bayesian interval estimates which are also confidence intervals","volume":"55","author":"Severini","year":"1993","journal-title":"Journal of the Royal Statistical Society. Series B (Methodological)"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0138|cit138","unstructured":"StataCorp LLC Stata\/SE 2017"},{"issue":"9930","key":"10.1002\/14651858.CD013103.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(14)60121-5","article-title":"Liver cirrhosis","volume":"383","author":"Tsochatzis","year":"2014","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD013103.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/ije\/dys041","article-title":"Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews","volume":"41","author":"Turner","year":"2012","journal-title":"International Journal of Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD013103.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/jrsm.1054","article-title":"Automating network meta-analysis","volume":"3","author":"Valkenhoef","year":"2012","journal-title":"Research Synthesis Methods"},{"issue":"9958","key":"10.1002\/14651858.CD013103.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0140-6736(14)61838-9","article-title":"Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis","volume":"384","author":"Williams","year":"2014","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD013103.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/gut.2010.236133","article-title":"Working party proposal for a revised classification system of renal dysfunction in patients with cirrhosis","volume":"60","author":"Wong","year":"2011","journal-title":"Gut"},{"issue":"7644","key":"10.1002\/14651858.CD013103.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013103.pub2-BIB0145|cit145","doi-asserted-by":"crossref","unstructured":"Yepes-Nunez JJ Li SA Guyatt G Jack SM Brozek JL Beyene J Development of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Summary of Findings (SoF) table for network meta-analysis Journal of Clinical Epidemiology 2019 [Epub ahead of print]","DOI":"10.1016\/j.jclinepi.2019.04.018"},{"issue":"9","key":"10.1002\/14651858.CD013103.pub2-BIB0146|cit146","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013103","article-title":"Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis","author":"Best","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD013103.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T09:21:39Z","timestamp":1663665699000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013103.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Hepato-Biliary Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,9,12]]},"references-count":148,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013103.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,12]]}}}